2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 745

Cardiac Involvements Are Related to Poor Prognosis in Patients with Takayasu’s Arteritis in China
Abstract Number: 326

Cardiac Sarcoidosis Awareness: Are We Underdiagnosing?
Abstract Number: 2327

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies
Abstract Number: L04

Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Abstract Number: 2439

Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis
Abstract Number: 1078

Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study
Abstract Number: 2136

Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Abstract Number: 2332

Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients
Abstract Number: 2676

Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Abstract Number: 349

Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study
Abstract Number: 2761

Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial
Abstract Number: 2411

Casting a Wide Net: Comparing Strategies for Recruiting 18-35-year-olds with Rheumatic Disease as Study Participants
Abstract Number: 1776

Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study
Abstract Number: 1089

Causes of Death in ANCA-Associated Vasculitis According to ANCA Type
Abstract Number: 1574

Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].